What We've Done - Arginetix, Inc.
Arginetix, Inc. was founded in 2007 by Acidophil in collaboration with Dr. David Christianson (University of Pennsylvania), Dan Berkowitz (Johns Hopkins University), and Gary Lessing, the company’s first CEO, to develop and commercialize novel therapeutic small molecule inhibitors of arginase. Arginase is an enzyme that competes with endothelial nitric oxide synthase (eNOS) for the use of the common substrate L-arginine. Elevated arginase levels limit L-arginine availability, reduce nitric oxide production, and contribute to endothelial dysfunction which leads to a variety disorders. Since its founding, Arginetix raised seed and Series A financing, merged with Immune Control in 2011 and became Corridor Pharmaceuticals which was acquired by AstraZeneca in 2014.